The Only FDA-Approved Treatment for Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis: Clinical Insights and a Caregiver Perspective

Overview

Hallucinations and delusions are common, underreported nonmotor symptoms of Parkinson’s disease (PD) that significantly impact patients and their caregivers. Attempting to manage hallucinations and delusions in patients with PD can present a therapeutic bind. Join Dr Barry Riskin for a presentation exploring these challenges as well as a review of the clinical efficacy and safety of a treatment option. Additionally, real-world evidence from 2 retrospective analyses investigating the risk of all-cause mortality among patients with PD psychosis treated with atypical antipsychotics will be presented.